CLINICAL TRIALS PROFILE FOR PERFLUTREN
✉ Email this page to a colleague
All Clinical Trials for PERFLUTREN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00398281 ↗ | Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 2006-11-01 | RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo followed by ultrasound-guided biopsy in finding prostate cancer. PURPOSE: This randomized phase III trial is studying dutasteride and ultrasound-guided biopsy to see how well they find prostate cancer compared with a placebo and ultrasound-guided biopsy. |
| NCT00398281 ↗ | Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer | Completed | Sidney Kimmel Cancer Center at Thomas Jefferson University | Phase 3 | 2006-11-01 | RATIONALE: Diagnostic procedures, such as ultrasound-guided biopsy, may help find prostate cancer. Dutasteride may improve the ability of ultrasound-guided biopsy to find prostate cancer. It is not yet known whether dutasteride followed by ultrasound-guided biopsy is more effective than a placebo followed by ultrasound-guided biopsy in finding prostate cancer. PURPOSE: This randomized phase III trial is studying dutasteride and ultrasound-guided biopsy to see how well they find prostate cancer compared with a placebo and ultrasound-guided biopsy. |
| NCT00507806 ↗ | Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke | Terminated | ImaRx Therapeutics | Phase 1/Phase 2 | 2005-03-01 | The study is designed to examine the safety, tolerability, and activity of a combination of microbubbles (perflutren lipid microsphere [Definity®]) and continuous monitoring with 2 MHz transcranial Doppler ultrasound (TCD) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke. |
| NCT00584402 ↗ | Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation | Completed | University of California, Davis | N/A | 2007-04-01 | The purpose of this study is to determine the efficacy of the Definity (perflutren lipid microsphere Injectable Suspension) ultrasound contrast agent in identifying small tumors (hepatomas & metastases) within the liver. Primary objective: To estimate the increase in conspicuity of small intrahepatic tumors with contrast-enhanced sonography Secondary Objectives: To estimate the effect of tumor type, size, location and depth on the conspicuity of small tumors on contrast-enhanced sonography |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PERFLUTREN
Condition Name
Clinical Trial Locations for PERFLUTREN
Trials by Country
Clinical Trial Progress for PERFLUTREN
Clinical Trial Phase
Clinical Trial Sponsors for PERFLUTREN
Sponsor Name
